| Expression pattern: |
UP |
| Associated gene: |
SCAP-129aa, PIK3R2, SH2C domain of PIK3R2, PIK3R2(P85beta), AKT, p-AKT |
| Associated microRNA: |
- |
| Biological function: |
circSCAP encodes SCAP-129aa and promotes platinum resistance in TNBC; silencing circSCAP restores cisplatin sensitivity, enhances cisplatin-induced apoptosis and DNA damage, while overexpression induces resistance, enhances cell viability and colony formation, and attenuates cisplatin-induced DNA damage. |
| Molecular mechanism: |
circSCAP encodes the peptide SCAP-129aa, which directly interacts with the SH2C domain of PIK3R2, inhibits PIK3R2 ubiquitination and proteasomal degradation, stabilizes PIK3R2 protein, and activates PI3K/AKT signaling to mediate platinum chemoresistance. |
| Biological pathway or process: |
PI3K/AKT (promotes); chemoresistance (promotes); drug resistance (promotes); apoptosis (inhibits); proliferation (promotes); ubiquitination (inhibits); other pathway/process (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; RNA-seq; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Co-IP; Luciferase Reporter Assay; Transfection; MTT; Colony Formation Assay; Annexin V/PI Flow Cytometry; TUNEL; In Vivo Animal Model; IHC (Immunohistochemistry); IF (Immunofluorescence); Western Blot; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
circSCAP and SCAP-129aa are proposed as biomarkers and therapeutic targets for platinum-resistant TNBC; SCAP-129aa high expression is associated with shorter overall survival, lymph node metastasis, distant metastasis, advanced AJCC stage, elevated Ki67 expression, and higher platinum resistance rate. |
| Description: |
circSCAP (hsa_circ_0007291) is a human SCAP-derived circular RNA upregulated in platinum-resistant TNBC. It encodes SCAP-129aa, which binds PIK3R2, prevents its ubiquitination-mediated degradation, activates PI3K/AKT signaling, and promotes cisplatin/platinum resistance. Silencing circSCAP re-sensitizes resistant TNBC models to platinum therapy, supporting circSCAP/SCAP-129aa as potential biomarkers and therapeutic targets. |
| Confidence score: |
0.8889 |